Herceptin biosimilar

South Korean biosimilar giant Celltrion Group aims to transform into a drug developer by generating 40% of sales from new medicines by 2030 as it is...

Celltrion Inc., South Korea’s largest biosimilar maker, said on Tuesday it has studied a possible acquisition of the biopharma solutions unit ...

Samsung Bioepis Co., a South Korean biosimilar firm, announced on Sunday that it has recently launched a new biosimilar drug called SB11 for the tre...

South Korea’s biosimilar giant Celltrion Group’s founder and Honorary Chairman Seo Jung-jin is readying to return to management just two...

Prestige Biopharma, a South Korean biopharmaceutical developer, said on Tuesday that the final analysis of phase 3 clinical trial on the anti-cancer...

Celltrion Healthcare Co. Ltd. said on Thursday that it launched Vegzelma, a biosimilar to the anti-cancer drug Avastin (active ingredient: bevacizum...

South Korea's biohealth company HK inno.N said on Wednesday that it has signed an agreement with Spanish pharmaceutical company mAbxience SA to intr...

South Korea's Celltrion Healthcare Co. on Tuesday said that for the second straight year, it landed an order for infliximab, an antibody used to tre...

South Korea's biosimilar heavyweight Celltrion Inc. has obtained permission from the Canadian health ministry to sell anticancer biosimilar Vegzelma...

South Korea's bio company Alteogen Inc. on Friday said it signed its fourth technology export contract since its 2018 development of the human recom...

South Korean biopharmaceutical company Celltrion Inc. announced Friday that it won its first trial against New York-based biotech giant Regeneron Ph...

Celltrion Inc., South Korea’s biopharmaceutical giant, made a foray into the digital healthcare sector for its future growth by launching a sm...

Celltrion Inc. secured Japan’s approval for sales of its cancer treatment biosimilar CT-P16, a move to help the South Korean biopharmaceutical...

Celltrion Healthcare Co., South Korean biopharmaceutical giant Celltrion Inc.'s global marketing affiliate, said on Friday it has obtained the Europ...

South Korea’s biopharmaceutical maker Celltrion Inc. on Friday reported strong quarterly earnings thanks to healthy demand for its biosimilar ...

NEW YORK – Samsung Bioepis Co., a biopharmaceutical unit of South Korea’s top conglomerate Samsung, is one step ahead of its rivals in t...

South Korea’s two major biopharmaceutical companies, Celltrion Inc. and Samsung Biologics Co., are respectively expecting more than 2 trillion...

Samsung Bioepis Co., a biopharmaceutical unit of Samsung Group, said its SB12, a proposed biosimilar to Alexion Pharmaceuticals Inc.’s rare bl...

South Korea's biopharmaceutical company Celltrion Inc. plans to sell all of its biosimilar products through its own sales channels in Europe to impr...

Samsung Bioepis Co., a biopharmaceutical unit of Samsung Group, plans to double the number of its biosimilar products on sale to 10 by 2025 and acce...

Samsung Bioepis Co., a biopharmaceutical unit of Samsung Group, said on Friday that sales of its five biosimilar products in global markets, excludi...

South Korea’s Celltrion Inc. has long been a biosimilar player, producing replicas of original drugs, a growing market in the pandemic era.Ear...

Samsung Bioepis Co., a leading South Korean biopharmaceutical company, has received approval from the US Food and Drug Administration for its Byoovi...

South Korea’s biopharmaceutical company Samsung Bioepis Co. won approval from European authorities for sale of Byooviz, its ophthalmology bios...

South Korea’s major drugmakers such as Celltrion Inc., Samsung Bioepis and Dong-A St are going for broke to release biosimilars of Stelara, Jo...

South Korean biosimilar companies such as Celltrion Inc. and Samsung Bioepis Co. are likely to see their sales hike by tens of millions of dollars...